SEARCH

SEARCH BY CITATION

References

  • 1
    Brunt EM, Janney CD, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
    Direct Link:
  • 2
    Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005; 41: 1313-1321.
  • 3
    Marchesini G, Bugianesi E, Forlani G, Cerelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. HEPATOLOGY 2003; 37: 917-923.
  • 4
    Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132-138.
  • 5
    Matteoni CA, Younossi SM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
  • 6
    Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140.
  • 7
    Sanyal AJ, Campbell-Sargeant C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192.
  • 8
    Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, et al. Gene expression of tumour necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. HEPATOLOGY 2001; 34: 1158-1163.
  • 9
    Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D et al. Plasma adiponectin is decreased in nonalcoholic liver disease. Eur J Endocrinol 2005; 152: 113-118.
  • 10
    Zamara E, Novo E, Marra F, Gentilini A, Romanelli RG, Caligiuri A, et al. 4-Hydroxynonenal as a selective pro-fibrogenetic stimulus for activated human hepatic stellate cells. J Hepatol 2004; 40: 60-68.
  • 11
    Merat S, Malekzadeh R, Sohrabi MR, Sotoudeh M, Rakhshani N, Sohrabpour AA, et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003; 38: 414-418.
  • 12
    Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003; 17: 713-718.
  • 13
    Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, et al. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 1946-1952.
    Direct Link:
  • 14
    Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 2485-2490.
    Direct Link:
  • 15
    Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-2307.
  • 16
    Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. HEPATOLOGY 2004; 39: 188-196.
  • 17
    Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
  • 18
    Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. HEPATOLOGY 2007; 46: 424-429.
  • 19
    Després JP, Golay A, Sjöström L, for the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134.
  • 20
    Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-1305.
  • 21
    Abdelmalek MF, Sanderson SO, Angulo P, Soldevila-Pico C, Liu CH, Peter J, et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. HEPATOLOGY 2009; 50: 1818-1826.
  • 22
    Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991; 12: 224-229.
  • 23
    Neumann M, Angulo P, Malkiewicz I, Jorgensen R, Shear N, Dickson ER, et al. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol 2002; 17: 196-202.
  • 24
    Bellentani S. Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: where are we and where should we go. Eur J Gastroenterol Hepatol 2005; 17: 137-140.
  • 25
    Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, et al. Ursodeoxycholic acid or clofibrate in the treatment of nonalcoholic-induced steatohepatitis: a pilot study. HEPATOLOGY 1996; 23: 1464-1467.
  • 26
    Dufour J-F, Oneta CM, Gonvers J-J, Bihl F, Cerny A, Cereda J-M, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4: 1537-1543.
  • 27
    Padda S, Ramirez FC, Shernhoff NJ. The effect of ursodeoxycholic acid (UDCA) treatment on liver tests in patients with non alcohol induced steatohepatitis (NASH). Am J Gastroenterol 1999; 94: A334.
  • 28
    Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. HEPATOLOGY 2004; 39: 770-778.
  • 29
    Ratziu V, De Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou CW, Renou C, et al. A multi-centric, double-blind, randomized-controlled trial (RCT) of high dose ursodeoxycholic acid in patients with non-alcoholic steatohepatitis (NASH) [Abstract]. J Hepatol 2009; 50( Suppl 1): S21.
  • 30
    Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. HEPATOLOGY 2009; 50: 291-308.
  • 31
    Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906.
  • 32
    Merriman RB, Ferrell LD, Patti MG, Weston SR, Pabst MS, Aouizerat BE, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. HEPATOLOGY 2006; 44: 874-880.
  • 33
    Fukusato T, Fukushima J, Shiga J, Takahashi Y, Nakano T, Maeyama S, et al. Interobserver variation in the histopathological assessment of nonalcoholic steatohepatitis. Hepatol Res 2005; 33: 122-127.
  • 34
    Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? HEPATOLOGY 2010; 51: 373-375.